PMID- 19395648
OWN - NLM
STAT- MEDLINE
DCOM- 20100525
LR  - 20131121
IS  - 1557-1246 (Electronic)
IS  - 1087-0547 (Linking)
VI  - 13
IP  - 5
DP  - 2010 Mar
TI  - Effects of extended-release guanfacine on ADHD symptoms and sedation-related 
      adverse events in children with ADHD.
PG  - 532-8
LID - 10.1177/1087054709332472 [doi]
AB  - OBJECTIVE: Guanfacine extended release (GXR) is a selective 
      alpha(2A)-adrenoceptor agonist that is shown to be an effective nonstimulant 
      treatment for the symptoms of attention-deficit/hyperactivity disorder. This 
      report documents the time course and predictors of symptom efficacy and 
      sedation-related adverse events (AEs) that emerge during GXR treatment throughout 
      3 randomized, placebo-controlled, double-blind trials of the drug. METHOD: 
      Analysis of data from 3 GXR clinical trials. RESULTS: Few variables related to 
      the study participants or their treatment regimen affects the emergence or 
      magnitude of sedation-related AEs. The best predictor of sedation is treatment 
      duration, with the likelihood of sedation-related AEs decreasing with increasing 
      time on medication. Sedation-related AEs are not predicted by the actual dose a 
      participant receives, the magnitude of any dose changes, or the relationship 
      between dose received and the magnitude of dose changes. Rates of discontinuation 
      because of sedation-related side effects average 6.3% for GXR-treated 
      participants and 0.5% for placebo-treated participants across the three trials. 
      CONCLUSION: These results suggest that acclimation to GXR may minimize the risk 
      for, and magnitude of, sedation-related AEs. (J. of Att. Dis. 2010; 13(5) 
      532-538).
FAU - Faraone, Stephen V
AU  - Faraone SV
AD  - SUNY Upstate Medical University, Department of Psychiatry and Behavioral 
      Sciences, 750 East AdamsStreet, Syracuse, NY, USA. faraones@upstate.edu
FAU - Glatt, Stephen J
AU  - Glatt SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090424
PL  - United States
TA  - J Atten Disord
JT  - Journal of attention disorders
JID - 9615686
RN  - 0 (Adrenergic alpha-Agonists)
RN  - 0 (Delayed-Action Preparations)
RN  - 30OMY4G3MK (Guanfacine)
SB  - IM
MH  - Adolescent
MH  - Adrenergic alpha-Agonists/administration & dosage/adverse effects
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy
MH  - Child
MH  - Delayed-Action Preparations
MH  - Dizziness/*chemically induced
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Fatigue/*chemically induced
MH  - Female
MH  - Guanfacine/*administration & dosage/*adverse effects
MH  - Humans
MH  - Male
MH  - Nausea/*chemically induced
MH  - Patient Selection
MH  - Randomized Controlled Trials as Topic
MH  - Regression Analysis
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2009/04/28 09:00
MHDA- 2010/05/26 06:00
CRDT- 2009/04/28 09:00
PHST- 2009/04/28 09:00 [entrez]
PHST- 2009/04/28 09:00 [pubmed]
PHST- 2010/05/26 06:00 [medline]
AID - 1087054709332472 [pii]
AID - 10.1177/1087054709332472 [doi]
PST - ppublish
SO  - J Atten Disord. 2010 Mar;13(5):532-8. doi: 10.1177/1087054709332472. Epub 2009 
      Apr 24.